KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Accumulated Expenses: 2009-2024

Historic Accumulated Expenses for Ionis Pharmaceuticals (IONS) over the last 16 years, with Dec 2024 value amounting to $108.4 million.

  • Ionis Pharmaceuticals' Accumulated Expenses fell 20.17% to $99.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $99.3 million, marking a year-over-year decrease of 20.17%. This contributed to the annual value of $108.4 million for FY2024, which is 26.68% down from last year.
  • Per Ionis Pharmaceuticals' latest filing, its Accumulated Expenses stood at $108.4 million for FY2024, which was down 26.68% from $147.9 million recorded in FY2023.
  • In the past 5 years, Ionis Pharmaceuticals' Accumulated Expenses registered a high of $147.9 million during FY2023, and its lowest value of $88.6 million during FY2021.
  • Its 3-year average for Accumulated Expenses is $132.1 million, with a median of $140.1 million in 2022.
  • Per our database at Business Quant, Ionis Pharmaceuticals' Accumulated Expenses spiked by 58.20% in 2022 and then dropped by 26.68% in 2024.
  • Over the past 5 years, Ionis Pharmaceuticals' Accumulated Expenses (Yearly) stood at $90.2 million in 2020, then fell by 1.78% to $88.6 million in 2021, then soared by 58.20% to $140.1 million in 2022, then climbed by 5.56% to $147.9 million in 2023, then fell by 26.68% to $108.4 million in 2024.